

SESSION 3 : THE WAY AHEAD



How to Meet the Challenges of Affordability of Novel Anti-Cancer Drugs?


*Eveline Scheres (Dutch Cancer Society)
Chair of The Access to Medicine Task force*

Accessibility: a complex discussion

- Promising new therapies, screening and medicine
- It has to be about the patient
 - Need for information and support
 - In touch with society?
 - How to involve patient?
- Teaming up to negotiate
- Price variation throughout Europe
- Accessibility is at stake and also no longer naturally in first world countries



The system has become a Gordian knot





CDDF MULTI-STAKEHOLDER WORKSHOP
ACCESS TO INNOVATIVE ONCOLOGY DRUGS IN EUROPE

| 7 - 8 September 2017
| Madrid, Spain

How to move forward from here?





Solving the problem implicates:

- Redefine normal
- A new solution is hard to find in an existing system (think outside the box)
- Let go of 'old arguments'
 - *The budget for medicine being constant over the last decade is not necessarily good news*
- Don't let fear be the main guidance
- Learn to speak each others language
- Cooperation between all stakeholders on an international level
- Building new bridges





What is innovation

- **I¹ = Improve**
 - *Refinement of the system*
- **I² = Transition**
 - *the change from a known system to an other known system*
- **Iⁿ = Transform/Renew**
 - *we don't now how the new system looks like*

- **It starts with people**
- **Take action**
- **Use your talent and show courage**
- **Walk the talk**

DCS Initiatives and agendasetting

Toegankelijkheid van dure kankergeneesmiddelen
Nu en in de toekomst

Signaleringscommissie Kanker van KWF Kankerbestrijding



Effectieve nieuwe middelen tegen kanker, maar het financieringssysteem kraakt

Belemmeringen en oplossingen bij de inzet van dure geneesmiddelen tegen kanker juli 2015




ECL
Association of European
Cancer Leagues

Access to Medicines Task Force

5 Components of Sustainable Access to Medicines

Next step: searching for solutions



- Remove patent obstacles
- The pharmaceutical industry as service provider
- Combine and accelerate
- Involve patients along the full trajectory of pharmaceutical development and its application in healthcare practice
- A stronger negotiating position

Cooperation on EU level via the ECL Access to Medicines Task Force



Principle goal:
To achieve equal access to medicines for all cancer patients in Europe

Goal 1:
Patients cannot suffer from a dysfunctional system and/or unsustainable financial and pricing arrangement in the prescription of medicines.

Short term:
Putting the most important dysfunctional elements and solutions within the health system on the political agenda

Goal 2:
Medicine prices should be sustainable and proportionate; Dialogue with the pharmaceutical industry is needed.

Short term:
Setting up a sustainable dialogue between pharma and independent patient representatives. (or with pharma and ECL TF)

Short term:
* Listing/ Acquisition prices of- and pricing policies for- innovative cancer drugs.

Goal 3:
The patients should be fully informed of the possible benefits and harms.

Short term:
Empowering patients to be able to actively partake in decisions concerning their own treatment. (apply learned capabilities and knowledge in the decision making process)

Goal 4:
Cancer societies in Europe should work together to get and keep this issue on the agenda.

Short term:
Create a knowledge exchange platform to share best practises concerning effective Public Affairs activities.

Goal 5:
Patients should at all times be involved in the decision-making process

Short term:
Getting the patient voice heard in all activities we undertake.

Accessibility based on fair prices

A Fair Price* is the price or the set of prices that allow access to medicine all over the world.

It has to be a price that is understandable and, as such, more legitimate based on objective factors: transparent, cost-effective and affordable for every country.

- Fair prices should consider the needs of all stakeholders involved: patients, buyers and shareholders.*
- Fair prices are profitable enough to ensure innovation and sustainable public health worldwide.*


**Suggestion made by
ECL Access to Medicine Taskforce*



CDDF MULTI-STAKEHOLDER WORKSHOP
ACCESS TO INNOVATIVE ONCOLOGY DRUGS IN EUROPE

7 - 8 September 2017
Madrid, Spain

A network that works for the patient



More information

Inspired by the initiative of the Dutch ministry of Health to form an international committee of the willing to cooperate on the subject of accessibility to cancer drugs in 2016, The Dutch Cancer Society initiated their own initiative which led to an [European Cancer League Access to Medicine Task Force in May 2016](#). Eveline is the first Chair of this task force. Ultimate goal of the task force is to achieve equal access to medicines for all cancer patients in Europe. At this moment 17 NGO's from 15 different countries are collaborating in this task force for the needs of cancer patients.



Eveline Scheres
Head of Public Affairs

Dutch Cancer Society
Delflandlaan 17 | PO Box 75508 | 1070 AM Amsterdam
T +31 207545630 | M +31 631641050 | E EScheres@kwf.nl
W www.kwf.nl

